Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study.

被引：0
|
作者：
Bartlett, Nancy
Brice, Pauline
Chen, Robert W.
Fanale, Michelle A.
Gopal, Ajay K.
Matous, Jeffrey
Rosenblatt, Joseph David
Grove, Laurie E.
Forero-Torres, Andres
机构：
[1] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[2] Hosp Saint Louis, Paris, France
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[6] Colorado Blood Canc Inst, Denver, CO USA
[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Seattle Genet Inc, Bothell, WA USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8027
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+Malignancies Resistant to Every 3 Week Brentuximab Vedotin
    Poston, Jacqueline N.
    Fromm, Jonathan R.
    Rasmussen, Heather A.
    Shustov, Andrei R.
    Libby, Edward N., III
    Smith, Stephen D.
    Gooley, Ted
    Gopal, Ajay K.
    BLOOD, 2017, 130
  • [42] CD30-Positive Cutaneous T-Cell Lymphoma and Response to Brentuximab Vedotin: 2 Illustrative Cases
    Mody, Kabir
    Wallace, Jill S.
    Stearns, Diane M.
    Bowers, George
    Lacy, Shannon R.
    Levy, Norman B.
    Zug, Kathryn A.
    Lansigan, Frederick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 319 - 323
  • [43] A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL
    Ahmed, Sairah
    Lisano, Julie
    Newhook, Trevor
    BLOOD, 2019, 134
  • [44] Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin
    Stein, Tomasz
    Robak, Tadeusz
    Biernat, Wojciech
    Robak, Ewa
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [45] Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
    Kim, Hee Kyung
    Moon, Seong Mi
    Moon, Ji Hoon
    Park, Jee Eun
    Byeon, Seonggyu
    Kim, Won Seog
    BLOOD RESEARCH, 2015, 50 (04) : 254 - 256
  • [46] Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Ishizawa, Kenichi
    Uike, Naokuni
    Uchida, Toshiki
    Suzuki, Tatsuya
    Aoki, Tomohiro
    Watanabe, Takashi
    Maruyama, Dai
    Yokoyama, Masahiro
    Takubo, Takatoshi
    Kagehara, Hideaki
    Matsushima, Takafumi
    CANCER SCIENCE, 2014, 105 (07) : 840 - 846
  • [47] Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management
    Scarisbrick, Julia J.
    FUTURE ONCOLOGY, 2017, 13 (27) : 2405 - 2411
  • [48] Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
    Herrera, Alex F.
    Zain, Jasmine
    Savage, Kerry J.
    Feldman, Tatyana
    Brammer, Jonathan E.
    Chen, Lu
    Puverel, Sandrine
    Popplewell, Leslie
    Budde, Lihua Elizabeth
    Mei, Matthew
    Hosing, Chitra
    Nair, Ranjit
    Leslie, Lori
    Daniels, Shari
    Peters, Lacolle
    Forman, Stephen
    Rosen, Steven
    Kwak, Larry
    Iyer, Swaminathan P.
    Haematol, Lancet
    LANCET HAEMATOLOGY, 2024, 11 (09): : e671 - e681
  • [49] Complete Remission of a CD30-positive large-cell anaplastic Lymphoma under Therapy with Brentuximab Vedotin (Adcetris®)
    Drescher, C.
    Mickler, M.
    Berneburg, M.
    Haferkamp, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 17 - 17
  • [50] The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
    Fanale, Michelle
    Bartlett, Nancy L.
    Forero-Torres, Andres
    Rosenblatt, Joseph
    Horning, Sandra J.
    Franklin, Anna R.
    Lynch, Carmel M.
    Sievers, Eric L.
    Kennedy, Dana A.
    BLOOD, 2009, 114 (22) : 1068 - 1069
12345